Fundraising FoxAmplyx Pharmaceuticals
San Diego, US · Delaware corporation · 8 known investors
Find your way into Amplyx Pharmaceuticals
Sign up to see every warm intro you have to Amplyx Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Amplyx Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Developing broad-spectrum antifungal agents for invasive fungal infections. (Acquired by Pfizer)
Founders & leadership
Board
Investors · 8
How we know: press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: RiverVest Venture Partners's portfolio page · a partner's Signal profile · press coverage · Not right? Tell us
How we know: Sofinnova Ventures's portfolio page · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: board seat on SEC Form D · press coverage · Not right? Tell us
Funding
SEC filings, press & company announcements$116.6M disclosed across 3 of 4 rounds · 2015–2020
- Undisclosed amountSeries C ExtensionMay 2020Source ↗
▶$91.3MraisedJan 2020 · 28 investors · PharmaceuticalsRule 506(b)
- Michael GreyDirector
- Ciara KennedyExecutive Officer, Director
- Paul GrintDirector
- Elaine HeronDirector
- Johan KordelDirector
- Edward MathersDirector
- Anand MehraDirector
- Alan FuhrmanExecutive Officer
- Mike HodgesExecutive Officer
- Niall ODonnellDirector
- Offering amount
- $102.7M
- Amount sold
- $91.3M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$23.7MraisedDec 2015 · 25 investors · PharmaceuticalsRule 506(b)
- Elaine HeronDirector
- Niall ODonnellDirector
- Ed MathersDirector
- Ciara KennedyExecutive Officer
- Michael GreyExecutive Officer, Director
- Mitchell MutzExecutive Officer
- Offering amount
- $49.2M
- Amount sold
- $23.7M
- First sale
- Oct 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedAug 2015 · 13 investors · PharmaceuticalsRule 506(b)
- Chrysa MineoDirector
- Jack FlorioDirector
- Elaine HeronDirector
- Mitchell MutzExecutive Officer, Director
- Santosh VetticadenDirector
- Karen TalmadgeDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Minimum investment
- $50K
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Amplyx Pharmaceuticals went on to found or lead other companies.
Frequently asked questions
- What does Amplyx Pharmaceuticals do?
- Developing broad-spectrum antifungal agents for invasive fungal infections. (Acquired by Pfizer)
- Who are Amplyx Pharmaceuticals's investors?
- Amplyx Pharmaceuticals's investors include New Enterprise Associates (NEA), Pappas Capital, RiverVest Venture Partners, Sofinnova Ventures, Arix Bioscience, Lundbeckfonden Ventures, Pappas Capital, Sofinnova Venture Partners.
- How much funding has Amplyx Pharmaceuticals raised?
- Amplyx Pharmaceuticals has disclosed $116.6M raised across 3 of its 4 known rounds.
- Where is Amplyx Pharmaceuticals headquartered?
- Amplyx Pharmaceuticals is headquartered in San Diego, US.